OncXerna Therapeutics reports final Phase 2 results and new biomarker data from its trial of bavituximab plus pembrolizumab in previously untreated advanced hepatocellular carcinoma. The company says its Xerna TME Panel identified participants more likely to respond to the combination.
OncXerna Therapeutics doses the first patient in a Phase 2 trial evaluating navicixizumab in patients with select advanced solid tumors. The study evaluates navicixizumab both alone and in combination with chemotherapy.
Exact Sciences and OncXerna Therapeutics enter an exclusive license agreement that expands access to OncXerna’s Xerna TME Panel laboratory services. The headline also reports a $190 million acquisition but does not identify its target or provide further details.
OncXerna Therapeutics reports new results from its Xerna RNA-based biomarker platform at the AACR Annual Meeting. The data support applying the Xerna TME Panel beyond gastric and ovarian cancers in prospectively driven trials with OncXerna’s clinical-stage programs.
